Engineered Dendritic Cell Vaccines for Multiple Myeloma
ConditionMultiple Myeloma or Plasmacytoma
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male and female subjects with multiple myeloma or plasmacytoma
Very good partial or complete remission (CR) after prior combination therapies.
Expected survival > 12 weeks
Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
Disqualifiers
Pregnant or lactating women
Uncontrolled active infection
HIV or active hepatitis B or hepatitis C infection
Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
Trial design
Design model
Single group
Treatments tested in this trial
DC vaccines
Biological/VaccineAntigen-presenting and immune modifying DCvacs to treat MM
Treatment groups
10 Participants
are divided into 1 treatment groupGroup A: DCvac cells to treat MMExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Safety of DC injection
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame
1 MonthSecondary outcomes
1
Clinical response
Anti-tumor activity of the DCvacs by examination of anti-cancer immunity by measurement of tumor burden
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: